facebook pixel Phone 212 693 530* *Fixed network call charges according to your tariff Search for your nearest Collection Point

212 693 530*

Collection Points

Phone 212 693 530* *Fixed network call charges according to your tariff

The Lipid Profile

Published: May 27, 2022

Circulatory system diseases are the leading cause of morbidity and mortality in Portugal. Due to their multifactorial nature, diseases of the circulatory system are primarily caused by abnormalities in the lipid profile, influenced by various lifestyle factors (sedentary lifestyle, exposure to tobacco, or poor dietary habits), hypertension, and diabetes, as well as by other non-modifiable factors such as advanced age, male gender, family history, or ethnicity. Dyslipidemia is diagnosed following an assessment of the lipid profile. A fasting lipid profile—including total cholesterol (TC), triglycerides (TG), HDL, and LDL—should be ordered for all adults over the age of 20 and repeated every 5 years. The screening age is adjusted for individuals with established atherosclerotic risk, such as those with diabetes, hypertension, smoking habits, obese individuals, those with a family history of early coronary artery disease (CAD) in a first-degree relative, or those with cholesterol > 240 mg/dL or familial dyslipidemia.

Coronary artery disease is associated with elevated levels of low-density lipoprotein cholesterol (LDL-C), and the therapeutic approach is determined by these levels; in high-risk patients, a target LDL-C level of <70 mg/dL must be achieved through treatment.

However, even in patients with LDL-C below 70 mg/dL and HDL-C above 42 mg/dL, the rate of acute coronary events remains significant: 29.6% in diabetic patients and 19.4% in non-diabetic patients; despite statin therapy, it is not possible to eliminate this residual risk or prevent the continuation of the atherogenic process. In this group of patients, in whom type 2 diabetes and metabolic syndrome predominate, classic laboratory parameters alone are not sufficient to effectively control cholesterol levels. On the other hand, in individuals such as those with a family history of dyslipidemia and in patients with a high coronary calcium score on imaging, a lipid profile with “normal” results is not a cause for reassurance.

Laboratory diagnostic methods have undergone significant advances in terms of sensitivity and specificity for defining lipid profiles. The solution lies in utilizing the heterogeneity of lipoproteins in terms of differences in their size, density, and chemical composition—differences that formed the basis for the refinement of Polyacrylamide Gel Lipoprotein Electrophoresis (PGLE).

This technique is the only one that allows for the isolation and quantification of cholesterol in its fractions and subfractions: VLDL; 3 intermediate bands (C, B, and A); IDL, residual lipoproteins, and lipoprotein (a); and 7 LDL subfractions: the large, non-atherogenic ones (LDL 1 and 2) and the small, dense, atherogenic ones (LDL 3, 4, 5, 6, and 7). Elevated VLDL cholesterol is associated with hypertriglyceridemia; elevated IDL and residual lipoprotein cholesterol increases vascular risk; elevated cholesterol in the LDL subfractions 3, 4, 5, 6, and 7 triples the risk of cardiovascular disease.

Another point highlighted by this technique is the emphasis placed on the study of hypertriglyceridemia, which is often accompanied by highly atherogenic particles; however, these are also common in a large number of patients with normal triglyceride levels (< 150 mg/dl). Furthermore, in our experience, it is common to encounter patients with apparently normal classic lipid parameters but with pronounced atherogenic risk phenotypes.

The results are presented in the form of color-coded graphs (atherogenic LDL in red, others in yellow, IDL in purple, and HDL in green), and each subfraction is accompanied by the amount of cholesterol. Each graph is accompanied by an interpretive report that allows for an immediate and easy reading of the atherogenic profile of the sample under study, clearly identifying which patients, despite altered lipid profile parameters, may or may not have lipid subfractions that confer an increased risk of cardiovascular disease.

fig1
fig2
fig3

Figure 1 Polyacrylamide Gel Lipoprotein Electrophoresis (PGLE) Report: Identifies up to 12 lipoprotein bands that are separated according to their size, revealing: 1 VLDL, 3 IDLs, 7 LDLs, and 1 HDL.

Figure 2. Lipoproteinogram without atherogenic subfractions, despite elevated total cholesterol and LDL cholesterol

Figure 3. Lipoproteinogram showing atherogenic LDL subfractions 3, 4, 5, and 6, despite normal levels of total cholesterol and LDL cholesterol, placing this patient at a threefold higher risk of coronary artery disease

The information provided by ELPG allows for the selection of individualized therapies, since different profiles require different treatments. This methodology is also recognized for its role in monitoring the efficacy of lipid-lowering therapy with statins, as a reversal of the pattern is observed in response to treatment.

fig4
fig5
 

 

Figures 4 and 5. Lipoproteinogram revealing the heterogeneity of LDL subfractions, identifying LDL subtypes 3 through 5, which are recognized as indicative of an atherogenic profile. After initiating statin therapy, the same patient was reevaluated and showed the disappearance of the atherogenic LDL fractions, demonstrating the efficacy of the therapy.

It is a precise method that is easily incorporated into routine practice.

The Germano de Sousa Laboratory Medicine Center is a pioneer in applying this methodology to the study of dyslipidemias in Portugal and, since 2011, has accumulated extensive experience, with the study of dyslipidemias representing one of the centers of excellence in our clinical-laboratory activity.

Margarida Albuquerque, MD, Department of Clinical Chemistry, Germano de Sousa Laboratory Medicine Center

If you have any questions, please contact us.
We'll be happy to help.

CLINICAL PATHOLOGY LABORATORY

CLINICAL PATHOLOGY LABORATORY
EMAIL

Phone 212 693 530*

*Fixed network call charges according to your tariff

Related news:

Related articles: